{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:17:01Z","timestamp":1768821421193,"version":"3.49.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1038\/s41417-024-00810-7","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T23:02:07Z","timestamp":1721689327000},"page":"1390-1401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic activity of retroviral replicating vector-mediated gene therapy in combination with anti-PD-1 antibody in a murine pancreatic cancer model"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6289-7680","authenticated-orcid":false,"given":"Hiroki","family":"Niwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3999-9627","authenticated-orcid":false,"given":"Toru","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Kushiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomotaka","family":"Kuraya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6205-9890","authenticated-orcid":false,"given":"Kazuho","family":"Inoko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Tsuchikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Shichinohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1349-4471","authenticated-orcid":false,"given":"Douglas J.","family":"Jolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6069-9082","authenticated-orcid":false,"given":"Noriyuki","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"810_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin."},{"key":"810_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326:851\u201362.","journal-title":"JAMA"},{"key":"810_CR3","doi-asserted-by":"publisher","first-page":"e017249","DOI":"10.1136\/bmjopen-2017-017249","volume":"8","author":"JC Lee","year":"2018","unstructured":"Lee JC, Ahn S, Cho IK, Lee J, Kim J, Hwang JH. Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis. BMJ Open. 2018;8:e017249.","journal-title":"BMJ Open"},{"key":"810_CR4","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33:828\u201333.","journal-title":"J Immunother."},{"key":"810_CR5","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl J Med. 2012;366:2455\u201365.","journal-title":"N. Engl J Med."},{"key":"810_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409\u201313.","journal-title":"Science"},{"key":"810_CR7","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","volume":"36","author":"JJ Luke","year":"2018","unstructured":"Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol. 2018;36:1611\u20138.","journal-title":"J Clin Oncol."},{"key":"810_CR8","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1158\/1078-0432.CCR-19-3978","volume":"26","author":"T Tsujikawa","year":"2020","unstructured":"Tsujikawa T, Crocenzi T, Durham JN, Sugar EA, Wu AA, Onners B, et al. Evaluation of Cyclophosphamide\/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in patients with pancreatic cancer. Clin Cancer Res. 2020;26:3578\u201388.","journal-title":"Clin Cancer Res."},{"key":"810_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/1078-0432.CCR-19-2078","volume":"26","author":"D Mahalingam","year":"2020","unstructured":"Mahalingam D, Wilkinson GA, Eng KH, Fields P, Raber P, Moseley JL, et al. Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: a phase ib study. Clin Cancer Res. 2020;26:71\u201381.","journal-title":"Clin Cancer Res."},{"key":"810_CR10","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-19-3624","volume":"26","author":"C Xie","year":"2020","unstructured":"Xie C, Duffy AG, Brar G, Fioravanti S, Mabry-Hrones D, Walker M, et al. Immune checkpoint blockade in combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma. Clin Cancer Res. 2020;26:2318\u201326.","journal-title":"Clin Cancer Res."},{"key":"810_CR11","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-0099","volume":"26","author":"ZA Wainberg","year":"2020","unstructured":"Wainberg ZA, Hochster HS, Kim EJ, George B, Kaylan A, Chiorean EG, et al. Open-label, phase I study of nivolumab combined with nab-Paclitaxel plus gemcitabine in advanced pancreatic cancer. Clin Cancer Res. 2020;26:4814\u201322.","journal-title":"Clin Cancer Res."},{"key":"810_CR12","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1634\/theoncologist.2019-0473","volume":"25","author":"SD Kamath","year":"2020","unstructured":"Kamath SD, Kalyan A, Kircher S, Nimeiri H, Fought AJ, Benson A 3rd, et al. Ipilimumab and gemcitabine for advanced pancreatic cancer: a phase Ib study. Oncologist. 2020;25:e808\u201315.","journal-title":"Oncologist"},{"key":"810_CR13","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","volume":"2","author":"AR Parikh","year":"2021","unstructured":"Parikh AR, Szabolcs A, Allen JN, Clark JW, Wo JY, Raabe M, et al. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat Cancer. 2021;2:1124\u201335.","journal-title":"Nat Cancer"},{"key":"810_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/cancers10040103","volume":"10","author":"M Sato-Dahlman","year":"2018","unstructured":"Sato-Dahlman M, Wirth K, Yamamoto M. Role of gene therapy in pancreatic cancer-a review. Cancers. 2018;10:103.","journal-title":"Cancers"},{"key":"810_CR15","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/14712598.2021.1902982","volume":"21","author":"SA Collins","year":"2021","unstructured":"Collins SA, Shah AH, Ostertag D, Kasahara N, Jolly DJ. Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer. Expert Opin Biol Ther. 2021;21:1199\u2013214.","journal-title":"Expert Opin Biol Ther."},{"key":"810_CR16","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1089\/104303401750195881","volume":"12","author":"CR Logg","year":"2001","unstructured":"Logg CR, Tai CK, Logg A, Anderson WF, Kasahara N. A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum Gene Ther. 2001;12:921\u201332.","journal-title":"Hum Gene Ther."},{"key":"810_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/neuonc\/nor199","volume":"14","author":"D Ostertag","year":"2012","unstructured":"Ostertag D, Amundson KK, Lopez Espinoza F, Martin B, Buckley T, Galvao da Silva AP, et al. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro Oncol. 2012;14:145\u201359.","journal-title":"Neuro Oncol"},{"key":"810_CR18","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.ymthe.2005.03.017","volume":"12","author":"CK Tai","year":"2005","unstructured":"Tai CK, Wang WJ, Chen TC, Kasahara N. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol Ther. 2005;12:842\u201351.","journal-title":"Mol Ther."},{"key":"810_CR19","doi-asserted-by":"publisher","first-page":"7108","DOI":"10.1158\/1078-0432.CCR-06-1452","volume":"12","author":"K Hiraoka","year":"2006","unstructured":"Hiraoka K, Kimura T, Logg CR, Kasahara N. Tumor-selective gene expression in a hepatic metastasis model after locoregional delivery of a replication-competent retrovirus vector. Clin Cancer Res. 2006;12:7108\u201316.","journal-title":"Clin Cancer Res."},{"key":"810_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1089\/hgtb.2015.106","volume":"27","author":"CG Twitty","year":"2016","unstructured":"Twitty CG, Diago OR, Hogan DJ, Burrascano C, Ibanez CE, Jolly DJ, et al. Retroviral replicating vectors deliver cytosine deaminase leading to targeted 5-Fluorouracil-mediated cytotoxicity in multiple human cancer types. Hum Gene Ther Methods. 2016;27:17\u201331.","journal-title":"Hum Gene Ther Methods"},{"key":"810_CR21","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41417-018-0020-7","volume":"25","author":"K Inoko","year":"2018","unstructured":"Inoko K, Hiraoka K, Inagaki A, Takahashi M, Kushibiki T, Hontani K, et al. Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer. Cancer Gene Ther. 2018;25:184\u201395.","journal-title":"Cancer Gene Ther"},{"key":"810_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1089\/hum.2014.100","volume":"26","author":"TT Huang","year":"2015","unstructured":"Huang TT, Parab S, Burnett R, Diago O, Ostertag D, Hofman FM, et al. Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model. Hum Gene Ther. 2015;26:82\u201393.","journal-title":"Hum Gene Ther."},{"key":"810_CR23","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.3390\/cancers14235820","volume":"14","author":"H Kushiya","year":"2022","unstructured":"Kushiya H, Hiraoka K, Suzuki T, Inoko K, Inagaki A, Niwa H, et al. Retroviral replicating vector Toca 511 (Vocimagene Amiretrorepvec) for prodrug activator gene therapy of lung cancer. Cancers. 2022;14:5820.","journal-title":"Cancers"},{"key":"810_CR24","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1038\/mt.2012.83","volume":"20","author":"OD Perez","year":"2012","unstructured":"Perez OD, Logg CR, Hiraoka K, Diago O, Burnett R, Inagaki A, et al. Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol Ther. 2012;20:1689\u201398.","journal-title":"Mol Ther."},{"key":"810_CR25","doi-asserted-by":"publisher","first-page":"107447","DOI":"10.1016\/j.pharmthera.2019.107447","volume":"206","author":"S Vodenkova","year":"2020","unstructured":"Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther. 2020;206:107447.","journal-title":"Pharmacol Ther."},{"key":"810_CR26","doi-asserted-by":"publisher","first-page":"341ra375","DOI":"10.1126\/scitranslmed.aad9784","volume":"8","author":"TF Cloughesy","year":"2016","unstructured":"Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med. 2016;8:341ra375.","journal-title":"Sci Transl Med."},{"key":"810_CR27","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/neuonc\/noy075","volume":"20","author":"TF Cloughesy","year":"2018","unstructured":"Cloughesy TF, Landolfi J, Vogelbaum MA, Ostertag D, Elder JB, Bloomfield S, et al. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro Oncol. 2018;20:1383\u201392.","journal-title":"Neuro Oncol"},{"key":"810_CR28","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","volume":"70","author":"J Vincent","year":"2010","unstructured":"Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70:3052\u201361.","journal-title":"Cancer Res"},{"key":"810_CR29","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3390\/cancers12061641","volume":"12","author":"WH Gmeiner","year":"2020","unstructured":"Gmeiner WH. Fluoropyrimidine modulation of the anti-tumor immune response-prospects for improved colorectal cancer treatment. Cancers. 2020;12:1641.","journal-title":"Cancers"},{"key":"810_CR30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s10147-014-0719-x","volume":"20","author":"Y Yamamura","year":"2015","unstructured":"Yamamura Y, Tsuchikawa T, Miyauchi K, Takeuchi S, Wada M, Kuwatani T, et al. The key role of calreticulin in immunomodulation induced by chemotherapeutic agents. Int J Clin Oncol. 2015;20:386\u201394.","journal-title":"Int J Clin Oncol."},{"key":"810_CR31","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/neuonc\/nox037","volume":"19","author":"LA Mitchell","year":"2017","unstructured":"Mitchell LA, Lopez Espinoza F, Mendoza D, Kato Y, Inagaki A, Hiraoka K, et al. Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model. Neuro Oncol. 2017;19:930\u20139.","journal-title":"Neuro Oncol"},{"key":"810_CR32","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/neuonc\/nox038","volume":"19","author":"K Hiraoka","year":"2017","unstructured":"Hiraoka K, Inagaki A, Kato Y, Huang TT, Mitchell LA, Kamijima S, et al. Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity. Neuro Oncol. 2017;19:918\u201329.","journal-title":"Neuro Oncol"},{"key":"810_CR33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.omto.2017.12.001","volume":"8","author":"K Yagiz","year":"2018","unstructured":"Yagiz K, Rodriguez-Aguirre ME, Lopez Espinoza F, Montellano TT, Mendoza D, Mitchell LA, et al. A retroviral replicating vector encoding cytosine deaminase and 5-FC induces immune memory in metastatic colorectal cancer models. Mol Ther Oncolytics. 2018;8:14\u201326.","journal-title":"Mol Ther Oncolytics"},{"key":"810_CR34","doi-asserted-by":"publisher","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-18-0619","volume":"24","author":"DJ Hogan","year":"2018","unstructured":"Hogan DJ, Zhu JJ, Diago OR, Gammon D, Haghighi A, Lu G, et al. Molecular analyses support the safety and activity of retroviral replicating vector Toca 511 in patients. Clin Cancer Res. 2018;24:4680\u201393.","journal-title":"Clin Cancer Res."},{"key":"810_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/13543784.2019.1572112","volume":"28","author":"BD Philbrick","year":"2019","unstructured":"Philbrick BD, Adamson DC. Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma. Expert Opin Investig Drugs. 2019;28:207\u201316.","journal-title":"Expert Opin Investig Drugs"},{"key":"810_CR36","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jamaoncol.2020.3161","volume":"6","author":"TF Cloughesy","year":"2020","unstructured":"Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, et al. Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a randomized clinical trial. JAMA Oncol. 2020;6:1939\u201346.","journal-title":"JAMA Oncol"},{"key":"810_CR37","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl J Med. 2011;364:1817\u201325.","journal-title":"N. Engl J Med."},{"key":"810_CR38","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl J Med. 2013;369:1691\u2013703.","journal-title":"N. Engl J Med."},{"key":"810_CR39","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","volume":"29","author":"PJ Loehrer Sr","year":"2011","unstructured":"Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an eastern cooperative oncology group trial. J Clin Oncol. 2011;29:4105\u201312.","journal-title":"J Clin Oncol"},{"key":"810_CR40","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","volume":"19","author":"B Chauffert","year":"2008","unstructured":"Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouch\u00e9 O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD\/SFRO study. Ann Oncol. 2008;19:1592\u20139.","journal-title":"Ann Oncol."},{"key":"810_CR41","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1158\/0008-5472.CAN-06-2563","volume":"67","author":"T Nakamura","year":"2007","unstructured":"Nakamura T, Fidler IJ, Coombes KR. Gene expression profile of metastatic human pancreatic cancer cells depends on the organ microenvironment. Cancer Res. 2007;67:139\u201348.","journal-title":"Cancer Res"},{"key":"810_CR42","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.2020.38.4_suppl.186","volume":"38","author":"GS Falchook","year":"2020","unstructured":"Falchook GS, Ahnert JR, Venkat S, Donahue A, Horner P, Thomassen A, et al. Immune modulation after Toca 511 and Toca FC treatment of colorectal cancer patients. J Clin Oncol. 2020;38:186\u2013186.","journal-title":"J Clin Oncol."},{"key":"810_CR43","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22:1865\u201374.","journal-title":"Clin Cancer Res."},{"key":"810_CR44","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.4049\/jimmunol.152.3.1127","volume":"152","author":"T Stalder","year":"1994","unstructured":"Stalder T, Hahn S, Erb P. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol. 1994;152:1127\u201333.","journal-title":"J Immunol."},{"key":"810_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08578-7","volume":"7","author":"A Malyshkina","year":"2017","unstructured":"Malyshkina A, Littwitz-Salomon E, Sutter K, Zelinskyy G, Windmann S, Schimmer S, et al. Fas Ligand-mediated cytotoxicity of CD4+ T cells during chronic retrovirus infection. Sci Rep. 2017;7:7785.","journal-title":"Sci Rep."},{"key":"810_CR46","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fimmu.2014.00174","volume":"5","author":"OA Haabeth","year":"2014","unstructured":"Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO. et al. How do CD4(+) T cells detect and eliminate tumor cells that either lack or express MHC Class II Molecules?. Front Immunol. 2014;5:174","journal-title":"Front Immunol"},{"key":"810_CR47","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1016\/j.immuni.2021.11.015","volume":"54","author":"DY Oh","year":"2021","unstructured":"Oh DY, Fong L. Cytotoxic CD4(+) T cells in cancer: expanding the immune effector toolbox. Immunity. 2021;54:2701\u201311.","journal-title":"Immunity"},{"key":"810_CR48","doi-asserted-by":"publisher","first-page":"755304","DOI":"10.3389\/fimmu.2021.755304","volume":"12","author":"S Gitto","year":"2021","unstructured":"Gitto S, Natalini A, Antonangeli F, Di Rosa F. The emerging interplay between recirculating and tissue-resident memory T cells in cancer immunity: lessons learned from PD-1\/PD-L1 blockade therapy and remaining gaps. Front Immunol. 2021;12:755304.","journal-title":"Front Immunol."},{"key":"810_CR49","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1084\/jem.183.5.2153","volume":"183","author":"F Di Rosa","year":"1996","unstructured":"Di Rosa F, Matzinger P. Long-lasting CD8 T cell memory in the absence of CD4 T cells or B cells. J Exp Med. 1996;183:2153\u201363.","journal-title":"J Exp Med."},{"key":"810_CR50","doi-asserted-by":"publisher","first-page":"eabb6852","DOI":"10.1126\/sciimmunol.abb6852","volume":"6","author":"YM Son","year":"2021","unstructured":"Son YM, Cheon IS, Wu Y, Li C, Wang Z, Gao X, et al. Tissue-resident CD4(+) T helper cells assist the development of protective respiratory B and CD8(+) T cell memory responses. Sci Immunol. 2021;6:eabb6852.","journal-title":"Sci Immunol"},{"key":"810_CR51","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.cell.2015.08.004","volume":"162","author":"S Eickhoff","year":"2015","unstructured":"Eickhoff S, Brewitz A, Gerner MY, Klauschen F, Komander K, Hemmi H, et al. Robust anti-viral immunity requires multiple distinct T cell-dendritic cell interactions. Cell. 2015;162:1322\u201337.","journal-title":"Cell"},{"key":"810_CR52","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.immuni.2015.07.020","volume":"43","author":"JL Hor","year":"2015","unstructured":"Hor JL, Whitney PG, Zaid A, Brooks AG, Heath WR, Mueller SN. Spatiotemporally distinct interactions with dendritic cell subsets facilitates CD4+ and CD8+ T cell activation to localized viral infection. Immunity. 2015;43:554\u201365.","journal-title":"Immunity"},{"key":"810_CR53","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.immuni.2017.10.009","volume":"47","author":"T Ahrends","year":"2017","unstructured":"Ahrends T, Spanjaard A, Pilzecker B, B\u0105ba\u0142a N, Bovens A, Xiao Y, et al. CD4(+) T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness. Immunity. 2017;47:848\u2013861.e845.","journal-title":"Immunity"},{"key":"810_CR54","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","volume":"18","author":"J Borst","year":"2018","unstructured":"Borst J, Ahrends T, B\u0105ba\u0142a N, Melief CJM, Kastenm\u00fcller W. CD4(+) T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018;18:635\u201347.","journal-title":"Nat Rev Immunol."},{"key":"810_CR55","doi-asserted-by":"publisher","first-page":"CT067","DOI":"10.1158\/1538-7445.AM2018-CT067","volume":"78","author":"J Merchan","year":"2018","unstructured":"Merchan J, Rodon J, Falchook G, Venkat S, Ostertag D, Tejera D, et al. A phase Ib study of Toca 511, a retroviral replicating vector, followed by Toca FC in patients with advanced cancer. Cancer Res. 2018;78:CT067.","journal-title":"Cancer Res"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-024-00810-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-024-00810-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-024-00810-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T13:25:07Z","timestamp":1726752307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-024-00810-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["810"],"URL":"https:\/\/doi.org\/10.1038\/s41417-024-00810-7","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"1 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DJJ is a former employee of Tocagen Inc., and NK is a former consultant to Tocagen Inc. KH is a former employee of Takeda Pharmaceutical Company Limited. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The animal study protocol was approved by the Animal Research Committee of Hokkaido Uni-versity (protocol code 2018-015, 19-0031, 19-0032, 20-0116 and 21-0028).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}